Cargando…

Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis

BACKGROUND: Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients who have failed first or second line therapy. Anlotinib is a potentially beneficial new treatment option for SCLC. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guocan, Cai, Qingshan, Xu, Xudong, Shen, Yanqin, Xu, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951826/
https://www.ncbi.nlm.nih.gov/pubmed/33705427
http://dx.doi.org/10.1371/journal.pone.0247494